-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31

Benzinga·10/07/2026 17:03:08
Listen to the news
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $31.